Table 2.
Variable | Categorisation | RAI-3 immunoreactivity | |||
---|---|---|---|---|---|
n analysable | lowb | abundantb | pc | ||
Clinicopathological data: | |||||
Tumour stagea | |||||
pT1 | 46 | 29 | 17 | 0.134 | |
pT2 | 74 | 31 | 43 | ||
pT3 | 12 | 5 | 7 | ||
pT4 | 24 | 13 | 11 | ||
Lymph node statusa | |||||
pN0 | 68 | 34 | 34 | 0.713 | |
pN1-3 | 83 | 44 | 39 | ||
Histological grade | |||||
G1 | 16 | 9 | 7 | 0.572 | |
G2 | 67 | 36 | 31 | ||
G3 | 72 | 33 | 39 | ||
Multifocality | |||||
unifocal tumour | 130 | 69 | 61 | 0.086 | |
multifocal tumour | 26 | 9 | 17 | ||
Histological type | |||||
ductal | 130 | 66 | 64 | 0.905 | |
lobular | 11 | 5 | 6 | ||
other | 13 | 6 | 7 | ||
Immunohistochemistry (IHC): | |||||
Oestrogen receptor status | |||||
negative (IRS 0–2) | 41 | 23 | 18 | 0.557 | |
positive (IRS 3–12) | 89 | 45 | 44 | ||
Progesterone receptor status | |||||
negative (IRS 0–2) | 95 | 46 | 49 | 0.765 | |
positive (IRS 3–12) | 41 | 21 | 20 | ||
HER2 status | |||||
weak (0–2+) | 109 | 51 | 58 | 0.638 | |
strong (3+) | 25 | 13 | 12 |
aAccording to UICC: TNM Classification of Malignant Tumours. 6th edn (2002) Sobin LH, Wittekind CH (eds) Wiley: New York
bRAI-3 immunoreactivity: low = IRS 0–4, abundant = IRS 5–12
cPearson test (two-sided), bold face representing significant data (P < 0.05)